

# Taking charge of clinical risk...

## CLINICAL RISK MANAGEMENT



BMJ  
Publishing Group

Edited by CHARLES VINCENT

Risk management has become a major issue in health care, and what reducing the probability of patients being harmed during treatment and minimising the subsequent consequences. This timely book is a unique source of reference for managers and clinicians keen to develop effective risk management, containing:

Practical advice on implementation, the underlying principles and recognising potential risks

Chapters on the clinical applications in various specialties, including anaesthesia, obstetrics, paediatrics, and psychiatry

Contributions from leaders in the field from the UK and USA

All the information needed to investigate complaints, deal with claims in the optimum way, and reduce the impact of litigation

*the definitive guide to improving the quality of care for your patients*

*Order your copy now*

ISBN 0 7279 0947 9 588 pages January 1996  
UK £34.95; Overseas £38.00 (BMA members £32.95; £36.00)

BMJ  
Publishing Group

## ...and other management concerns


### Quality and Safety in Anaesthesia

Edited by Jonathan Secker Walker

"It is satisfying to find a text that states what quality in anaesthetic practice is really about."

*Today's Anaesthetist*

ISBN 0 7279 0828 6  
192 pages  
UK £16.95;  
Overseas £19.00  
(BMA members  
£15.95; £18.00)



### Outcomes into Clinical Practice

Edited by Tony Delamothe

A ground-breaking research, focusing on the opportunities to improve clinical effectiveness and set standards for good practice.


ISBN 0 7279 0888 X  
169 pages UK £17.95; Overseas £20.00  
(BMA members £16.95; £19.00)



### Rationing in Action

Expert advice on the implications of rationing to health providers and their patients.

ISBN 0 7279 0813 8 160 pages  
UK £10.95;  
Overseas £13.00  
(BMA members  
£9.95; £12.00)



### Management for Doctors

Edited by Jenny Simpson and Richard Smith

"An insightful and inspiring guide for any doctor who wants to know and understand more about NHS management."

*Journal of the Royal College of Physicians*

ISBN 0 7279 0858 8  
200 pages UK £12.95; Overseas £15.00  
(BMA members £11.95; £14.00)



### ORDER FORM

Available from: BMJ Publishing Group, P.O. Box 295, London WC1H 9TE (Tel: 0171 383 6185/6245), medical booksellers or the BMJ bookshop in BMA House

Please send me

- copy/ies of Clinical Risk Management
- copy/ies of Quality and Safety in Anaesthesia
- copy/ies of Outcomes into Clinical Practice
- copy/ies of Rationing in Action
- copy/ies of Management for Doctors

BMA Membership No. \_\_\_\_\_

Name \_\_\_\_\_  
(Print clearly)

Address \_\_\_\_\_

\_\_\_\_\_

Postcode \_\_\_\_\_

Cheque enclosed (made payable to British Medical Journal) £ \_\_\_\_\_

Debit my American Express/Visa/Mastercard

Card No. \_\_\_\_\_ Exp \_\_\_\_\_

Signature \_\_\_\_\_

Please send me a BMJ Publishing Group Catalogue

**PRESCRIBING INFORMATION**

**Presentations:** Pulmicort Respules, (2ml single dose unit ampoules) containing 0.25mg/ml or 0.5mg/ml budesonide in a suspension for nebulisation. **Uses:** Bronchial asthma where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate. **Dosage and administration:** Dosage schedules: Administer from suitable nebulisers. Dose delivered to the patient varies depending on the nebulising equipment used (see data sheet). Adjust dosage individually. Initially during periods of severe asthma and while reducing or discontinuing oral glucocorticosteroids the recommended dose in adults (including elderly and children 12 years and older) is usually 1-2mg twice daily. In very severe cases the dosage may be further increased. Children 3 months to 12 years: 0.5-1mg twice daily. The maintenance dose should be the lowest dose which keeps the patient symptom-free. Recommended doses are: Adults (including elderly and children 12 years and older): 0.5-1mg twice daily. Children (3 months to 12 years): 0.25-0.5mg twice daily. For an increased therapeutic effect increase dose of Pulmicort rather than combine treatment with oral corticosteroids because of the lower risk of systemic effects. **Contra-indications, warnings, etc.:** Contra-indications: Hypersensitivity to any of the constituents. Special warnings and precautions: Care is needed in patients with pulmonary tuberculosis and viral infections in the airways. A short course of oral steroids in addition to Pulmicort may be required in patients with excessive mucus in the bronchi. Transfer of patients dependent on oral steroids to Pulmicort demands special care: see data sheet for further details. The nebuliser chamber should be cleaned and dried after every administration. Pulmicort does not affect the ability to drive and use machines. Pulmicort Respules can be mixed with 0.9% saline and with solutions of terbutaline, salbutamol, sodium cromoglycate or ipratropium bromide. **Side-effects:** Mild irritation in the throat, coughing and hoarseness and oral candidiasis have been reported. In rare cases inhaled drugs may provoke bronchoconstriction in hyperreactive patients. Facial skin should be washed after use of the face mask as irritation can occur. Coughing can usually be prevented by inhaling a  $\beta_2$ -agonist (e.g. terbutaline) 5-10 minutes before inhalation of Pulmicort Respules. Avoid in pregnancy. **Pharmaceutical precautions:** Store below 30°C. Use within 3 months of opening the foil envelope. Protect opened ampoule from light. Use within 12 hours of opening. **Legal status:** POM. **Basic NHS price:** Pulmicort Respules 0.25mg/ml (20 single dose units) £32.00. Pulmicort Respules 0.5mg/ml (20 single dose units) £44.64. **Product licence nos.:** Pulmicort Respules 0.25mg/ml PL 0017/0309. Pulmicort Respules 0.5mg/ml PL 0017/0310. **Name and address of Product Licence holder:** Astra Pharmaceuticals Ltd., Home Park, Kings Langley, Herts WD4 8DH.

# Inspired control from their early months



**Pulmicort**  
**Respules**  
BUDESONIDE

Nebulised Steroid Control

**ASTRA**  
Astra Pharmaceuticals

© Registered Trademark  
Date of preparation: May 1995  
P.Res. 0524